CA2151045A1 - Platelet-activating factor acetylhydrolase - Google Patents

Platelet-activating factor acetylhydrolase

Info

Publication number
CA2151045A1
CA2151045A1 CA002151045A CA2151045A CA2151045A1 CA 2151045 A1 CA2151045 A1 CA 2151045A1 CA 002151045 A CA002151045 A CA 002151045A CA 2151045 A CA2151045 A CA 2151045A CA 2151045 A1 CA2151045 A1 CA 2151045A1
Authority
CA
Canada
Prior art keywords
platelet
activating factor
factor acetylhydrolase
acetylhydrolase
expected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002151045A
Other languages
French (fr)
Other versions
CA2151045C (en
Inventor
Laurence S. Cousens
Christine D. Eberhardt
Patrick Gray
Hai Le Trong
Larry W. Tjoelker
Cheryl L. Wilder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Laurence S. Cousens
Christine D. Eberhardt
Patrick Gray
Hai Le Trong
Larry W. Tjoelker
Cheryl L. Wilder
Icos Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurence S. Cousens, Christine D. Eberhardt, Patrick Gray, Hai Le Trong, Larry W. Tjoelker, Cheryl L. Wilder, Icos Corporation filed Critical Laurence S. Cousens
Publication of CA2151045A1 publication Critical patent/CA2151045A1/en
Application granted granted Critical
Publication of CA2151045C publication Critical patent/CA2151045C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.
CA002151045A 1993-10-06 1994-10-06 Platelet-activating factor acetylhydrolase Expired - Lifetime CA2151045C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13380393A 1993-10-06 1993-10-06
US08/133,803 1993-10-06
PCT/US1994/011340 WO1995009921A1 (en) 1993-10-06 1994-10-06 Platelet-activating factor acetylhydrolase

Publications (2)

Publication Number Publication Date
CA2151045A1 true CA2151045A1 (en) 1995-04-13
CA2151045C CA2151045C (en) 2002-04-30

Family

ID=22460373

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002151045A Expired - Lifetime CA2151045C (en) 1993-10-06 1994-10-06 Platelet-activating factor acetylhydrolase

Country Status (12)

Country Link
US (5) US5641669A (en)
EP (3) EP0673426B1 (en)
JP (3) JP3613398B2 (en)
AT (2) ATE315655T1 (en)
CA (1) CA2151045C (en)
DE (2) DE69434609T2 (en)
DK (2) DK0673426T3 (en)
ES (2) ES2159573T3 (en)
GR (1) GR3036535T3 (en)
HK (2) HK1012023A1 (en)
PT (1) PT673426E (en)
WO (1) WO1995009921A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423436T2 (en) 1993-06-25 2000-09-07 Smithkline Beecham Plc PHOSPHOLIPASE A2 TIED TO LIPOPROTEIN, INHIBITORS THEREOF AND THEIR USE FOR DIAGNOSIS AND THERAPY
JP3563091B2 (en) * 1993-08-03 2004-09-08 第一サントリーファーマ株式会社 Oxidized phospholipid degrading enzymes and their genes
US6146625A (en) * 1993-10-06 2000-11-14 Icos Corporation Platelet-activating factor acetylhydrolase
EP0853673A1 (en) * 1995-09-29 1998-07-22 Smithkline Beecham Plc COMPOUND HAVING SEQUENCE HOMOLOGY WITH LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 (Lp-PLA2)/PAF ACETYL HYDROLASE
JP2002515728A (en) * 1995-09-29 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー New applications
JP2000502079A (en) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Monocyclic .BETA.-lactam derivatives for the treatment of atherosclerosis
US6166292A (en) * 1996-04-26 2000-12-26 Ajinomoto Co., Inc. Raffinose synthetase gene, method of producing raffinose and transgenic plant
EP0915843A1 (en) * 1996-04-26 1999-05-19 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atheroscleroses
US6891084B1 (en) * 1996-04-26 2005-05-10 Ajinomoto Co., Inc. DNA encoding raffinose synthase from soybean
JPH1017600A (en) * 1996-06-28 1998-01-20 Suntory Ltd Blood platelet activating factor acetyl hydrolase and its gene
AU751594B2 (en) * 1997-08-13 2002-08-22 Icos Corporation Truncated platelet-activating factor acetylhydrolase
EP1124970A1 (en) * 1998-10-28 2001-08-22 Smithkline Beecham Plc Process of purification of low density lipoprotein associated phospholipase a2 using immobilized metal affinity chromatography
GB9923790D0 (en) * 1999-10-08 1999-12-08 Isis Innovation Immunoregulatory compositions
CN1179952C (en) * 2000-02-16 2004-12-15 史密斯克莱·比奇曼公司 Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
WO2002097055A2 (en) 2001-05-30 2002-12-05 Ryan James W Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase a2
US7475248B2 (en) 2002-04-29 2009-01-06 International Business Machines Corporation Enhanced message security
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
PL1633864T3 (en) 2003-05-28 2010-09-30 Glaxo Group Ltd High throughput assay of lp-pla2 activity
WO2005074604A2 (en) 2004-02-03 2005-08-18 Diadexus, Inc. METHODS OF DETECTING Lp-PLA2 ACTIVITY
US7741020B2 (en) * 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
JP2007145814A (en) * 2005-10-28 2007-06-14 Bizen Chemical Co Ltd Platelet activating factor receptor antagonist and composition
BRPI0710482A2 (en) * 2006-04-21 2011-08-16 Wyeth Corp methods for selecting high throughput cell lines
WO2008141176A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
EA200971050A1 (en) 2007-05-11 2010-06-30 Томас Джефферсон Юниверсити METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS
US8257697B2 (en) * 2007-10-31 2012-09-04 Allertech Laboratory Inc. Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis
JP2009005705A (en) * 2008-07-02 2009-01-15 Icos Corp Platelet-activating factor acetylhydrolase
JP5596964B2 (en) * 2008-12-02 2014-09-24 協和メデックス株式会社 Method for producing standard product for fractional determination of components in lipoprotein
WO2012080497A2 (en) 2010-12-17 2012-06-21 Glaxo Group Limited Methods of treatment and prevention of eye diseases
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
CN105542010B (en) * 2015-12-31 2020-11-03 武汉华美生物工程有限公司 Lipoprotein-associated phospholipase A2 monoclonal antibody, antibody pair, preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
GB9313144D0 (en) 1993-06-25 1993-08-11 Smithkline Beecham Plc Compounds
DE69423436T2 (en) * 1993-06-25 2000-09-07 Smithkline Beecham Plc PHOSPHOLIPASE A2 TIED TO LIPOPROTEIN, INHIBITORS THEREOF AND THEIR USE FOR DIAGNOSIS AND THERAPY
GB9400413D0 (en) 1994-01-11 1994-03-09 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
JP2004129671A (en) 2004-04-30
DE69434609D1 (en) 2006-04-06
GR3036535T3 (en) 2001-12-31
ES2258955T3 (en) 2006-09-16
ATE201905T1 (en) 2001-06-15
EP0673426A1 (en) 1995-09-27
JP3759941B2 (en) 2006-03-29
WO1995009921A1 (en) 1995-04-13
US20050100540A1 (en) 2005-05-12
EP1634953A2 (en) 2006-03-15
HK1012023A1 (en) 1999-07-23
DK0673426T3 (en) 2001-08-27
US5698403A (en) 1997-12-16
DE69427392T2 (en) 2002-05-23
ES2159573T3 (en) 2001-10-16
EP1096016A1 (en) 2001-05-02
EP0673426B1 (en) 2001-06-06
HK1038587A1 (en) 2002-03-22
EP1634953A3 (en) 2006-06-28
PT673426E (en) 2001-11-30
US5605801A (en) 1997-02-25
JP3613398B2 (en) 2005-01-26
ATE315655T1 (en) 2006-02-15
JPH08504603A (en) 1996-05-21
DE69434609T2 (en) 2006-09-21
DE69427392D1 (en) 2001-07-12
EP1096016B1 (en) 2006-01-11
DK1096016T3 (en) 2006-05-29
US5532152A (en) 1996-07-02
US5641669A (en) 1997-06-24
JP2006056901A (en) 2006-03-02
CA2151045C (en) 2002-04-30

Similar Documents

Publication Publication Date Title
CA2151045A1 (en) Platelet-activating factor acetylhydrolase
AU7565694A (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
AU1378595A (en) Methods and compositions for increasing the benefits of Rhizobium inoculation to legume crop productivity
PL308537A1 (en) Method of obtaining highly purified isomers of benzenodicarboxylic acids
EP0731773A4 (en) Production of h 2?-rich gas
AU3105793A (en) Process for purifying acrylic acid in high purity in the production of acrylic acid
GB2261789B (en) Improvements in or relating to the production of anaglyphs
CA2267994A1 (en) Truncated platelet-activating factor acetylhydrolase
CA2141563A1 (en) Novel 2-Substituted Indane-2-Mercaptoacetylamide Tricyclic Derivatives Useful as Inhibitors of Enkephalinase
AU6115194A (en) Novel peptide having esterase inhibitory activity and methodof producing same
AU680014B2 (en) Process for the desensitisation to intercrystalline corrosion of 2000 and 6000 series A1 alloys and corresponding products
CA2108358A1 (en) Gene expression in bacilli
IL110892A (en) Recombinant alpha-galactosidase enzyme methods for the production thereof and methods for utilizing the same
AU6478390A (en) Process for compensating the harmful effects of impurities of n-dichlorophosphoryl-trichlorophosphazene and its polycondensation product
GB9301683D0 (en) Improvements in or relating to the arrangements of loads
GB2284417B (en) Process for the production of spherulitic nitroguanidine
GB2288398B (en) Monomeric and oligomeric bisphenyl-HALS phosphites as stabilizers
GB9325106D0 (en) Improvements in or relating to the manufacture of similar components
AU7404591A (en) Alpha-amylase inhibitor obtained from soy-bean and production process therefor
ZA945874B (en) Process for improving the grinding of raw materials
ZA946619B (en) Production of diffluoromethane
GB2274972B (en) Improvements relating to the manufacture of hats
HU9503926D0 (en) Process for the production of detergent composition
HU9200576D0 (en) Process for the production of human originated lecithin
AU2902889A (en) Improvements in or relating to the repair of electrical circuits

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141006